Experon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.90 M
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.90 M
- Revenue Growth -36.14%
- Profit Growth -17.08%
- Ebitda 76.20%
- Net Worth 2.22%
- Total Assets 6.60%
About Experon Pharmaceuticals
Experon Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 May 2017 (Seven years and nine months 10 days old ). Its registered office is in Gorakhpur, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹0.90 M.
Aadarsh Vijay and Shobhna Khare serve as directors at the Company.
Company Details
-
Location
Gorakhpur, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2017PTC092775
-
Company No.
092775
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 May 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Experon Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aadarsh Vijay
|
Director | 01-May-2017 | Current |
|
Shobhna Khare
|
Director | 01-May-2017 | Current |
Financial Performance of Experon Pharmaceuticals.
Experon Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 36.14% decrease. The company also saw a substantial fall in profitability, with a 17.08% decrease in profit. The company's net worth moved up by a moderate rise of 2.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Experon Pharmaceuticals?
In 2021, Experon Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.90 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Dec 2019 | Others | ₹0.90 M | Open |
How Many Employees Work at Experon Pharmaceuticals?
Unlock and access historical data on people associated with Experon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Experon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Experon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.